Purple Biotech reports positive trial results for CM24 and NT219, advancing toward biomarker-driven studies and expanding its oncology pipeline. Purple Biotech Ltd. announced positive results from ...
Purple Biotech Ltd. announced significant progress in its clinical development pipeline during the AACR Annual Meeting 2025, providing updates on its therapies CM24 and NT219, and progressing toward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback